Collectively, these results suggest that the TGF-β/CLDN4/TNF-α/NF-κB signaling axis plays a critical role in glioma progression, and its disruption may offer a promising therapeutic strategy for GBM (39). Here, CLDN4 is linked to central nervous system cancer.